3-[2-[2-(2-Propoxyethoxy)ethoxy]ethoxy]propanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-[2-[2-(2-Propoxyethoxy)ethoxy]ethoxy]propanamide
• 英文别名: 3-[2-[2-(2-propoxyethoxy)ethoxy]ethoxy]propanamide
• 化学式: C₁₂H₂₅NO₅
• 分子量: 263.33
• InChiKey: NUANDBSBCPRWNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  18
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  80
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS NUCLÉOTIDIQUES ET LEURS MÉTHODES D'UTILISATION
  申请人：UNIV COLUMBIA

  公开号：WO2017205336A1

  公开（公告）日：2017-11-30

  Disclosed herein, inter alia, are compounds, compositions, and methods of thereof in the sequencing a nucleic acid.

  本公开的内容包括化合物、组合物以及在核酸测序中的方法。
• KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY
  申请人：Bracco Suisse S.A.

  公开号：US20140161732A1

  公开（公告）日：2014-06-12

  The present invention provides polypeptides, peptide dimers, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K D <1 μM), and dimer and multimeric constructs comprising these polypeptides, particularly contrast agents. Also provided are methods for monitoring and evaluating the therapeutic effectiveness of treatment protocols for diseases associated with angiogenesis or endothelial cell hyperproliferation, such as cancer, using contrast agents of the invention.

  本发明提供了多肽、肽二聚体和多聚复合物，包括至少一个结合KDR或VEGF/KDR复合物的结合基团，其在治疗、检测、分离或定位血管生成有优势的各种用途。特别公开了合成、分离的多肽，能够与KDR或VEGF/KDR复合物高亲和力结合（例如，具有KD<1微米），以及包含这些多肽的二聚体和多聚体构造，特别是对比剂。还提供了使用本发明的对比剂监测和评估与血管生成或内皮细胞过度增殖相关的疾病的治疗方案的治疗效果的方法，例如癌症。
• COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS
  申请人：Ardelyx, Inc.

  公开号：EP2887963B1

  公开（公告）日：2017-07-19
• Chelated PSMA Inhibitors
  申请人：Cancer Targeted Technology LLC

  公开号：US20190309000A1

  公开（公告）日：2019-10-10

  Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. Also provided are compositions including a compound of Formula (I) together with a pharmaceutically acceptable carrier, and methods for imaging prostate cancer cells.
• US9408926B2
  申请人：——

  公开号：US9408926B2

  公开（公告）日：2016-08-09